Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Delcath Says Hemofiltration Cartridge Gets CE Mark Approval

Oncology-based pharma and medical device company Delcath Systems, Inc. (DCTH: Quote) announced the receipt of CE Mark approval for the second-generation hemofiltration cartridge of its proprietary Hepatic CHEMOSAT Delivery System, allowing the company to now supply second-generation CHEMOSAT system to centers in Europe.

With the new hemofiltration cartridge, the company said, the CHEMOSAT system carries the same broad indication as the previous generation system, permitting physicians to use the product for the percutaneous intra-arterial administration of a chemotherapeutic agent to the liver to any patient who in their opinion may benefit.

"With the new hemofiltration cartridge, we believe that CHEMOSAT may help to improve the management of side effects on treated patients and potentially complement other systemic cancer therapies, leading to greater system utilization. We look forward to the first European commercial procedure using the new filter, which is scheduled for next week," Eamonn Hobbs, President & CEO of Delcath Systems said in a statement.

The approval from CE Mark allows Delcath to market and sell its Class III medical device in countries in the European Economic Area, or EEA. Delcath's new hemofiltration cartridge's design and technology is patent pending.

Register
To receive FREE breaking news email alerts for Delcath Systems Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.